rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AMLX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Amylyx Pharmaceuticals, Inc. (AMLX) Presents at ObesityWeek 2026 Annual Meeting - Slideshow

      2026-11-18. The following slide deck was published by Amylyx Pharmaceuticals, Inc.

      5h agoSeeking AlphaAMLX
      Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia - Slideshow

      2026-11-15. The following slide deck was published by Amylyx Pharmaceuticals, Inc.

      Nov 15Seeking AlphaAMLX
      Amylyx avexitide trial meets primary endpoint for hypoglycemia
      Nov 14Investing.comAMLX
      Amylyx at Stifel 2026 healthcare conference: avexitide nears launch
      Nov 10Investing.comAMLX
      Amylyx at Guggenheim conference: avexitide nears key launch step
      Nov 9Investing.comAMLX
      Why Amylyx Pharmaceuticals Stock Is Up 6.8% And What's Next
      Nov 8Yahoo FinanceAMLX
      Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results

      Amylyx Pharmaceuticals has delivered a very strong year to date share price gain. With that kind of move on the board, the key issue for you now is whether the stock price still lines up with the company’s book value. A year to date return of 158.3% puts real pressure on the question of whether Amylyx’s current market value is still grounded in its underlying net assets. Positive Phase 3 LUCIDITY trial results for avexitide and a cash balance reported at US$768.1m after a recent equity raise...

      Nov 7Yahoo FinanceAMLX
      Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified?
      Nov 7Yahoo FinanceAMLX
      Amylyx Pharmaceuticals Inc (AMLX) Q3 2026 Earnings Call Highlights: $768 Million Cash Position ...

      Amylyx Pharmaceuticals Inc (AMLX) enters Q3 2026 with a strengthened balance sheet and a clear regulatory path toward a potential 2027 launch of avexitide for post-bariatric hypoglycemia.

      Nov 7Yahoo FinanceAMLX
      Amylyx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceAMLX
      Amylyx Pharmaceuticals Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceAMLX
      Stifel reiterates Buy rating on Amylyx stock ahead of data
      Nov 5Investing.comAMLX
      Amylyx Pharmaceuticals earnings up next as drug approval looms
      Nov 4Investing.comAMLX
      Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
      Nov 3Yahoo FinanceAMLX
      Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
      Nov 2Yahoo FinanceAMLX
      Amylyx Pharmaceuticals shares may move 3.6% on earnings
      Oct 30Investing.comAMLX
      Amylyx Pharmaceuticals Insider Sold Shares Worth $830,904, According to a Recent SEC Filing
      Oct 7Yahoo FinanceAMLX
      Amylyx to present phase 3 avexitide data at ObesityWeek 2026
      Oct 6Investing.comAMLX
      Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
      Oct 6Yahoo FinanceAMLX
      Amylyx Pharma Q2 2026 Earnings Call Transcript - Amylyx Pharmaceuticals (NASDAQ:AMLX)

      Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our

      Oct 5BenzingaAMLX
      Amylyx Pharmaceuticals And 2 More Quality Growth Stocks

      The Federal Reserve just lifted interest rates again to tackle stubborn inflation, which puts real pressure on weaker balance sheets and slow growing businesses. In this environment, investors may focus on companies that analysts expect to grow earnings solidly while keeping finances in reasonable shape. This article breaks down three such high potential US stocks from our quality growth list, explaining what sets each apart and where the key risks sit. The stocks covered below are just a...

      Oct 4Yahoo FinanceAMLX
      Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

      Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end. PBH is a chroni

      Oct 3Yahoo FinanceAMLX
      Stifel reiterates Amylyx stock rating on avexitide confidence
      Oct 1Investing.comAMLX
      Amylyx at Stifel 2026 virtual cardiometabolic forum: avexitide gains
      Sep 30Investing.comAMLXSF
      Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

      CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

      Sep 23Yahoo FinanceAMLXSF
      Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

      CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

      Sep 8Yahoo FinanceAMLXMS
      Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

      Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

      Aug 30Yahoo FinanceAMLXLLY
      Guggenheim raises Amylyx stock price target on financing, trial data
      Aug 27Investing.comAMLX
      Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

      Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

      Aug 23The Globe and MailAMLX
      Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

      The biotech delivered excellent news from the laboratory.

      Aug 21Yahoo FinanceAMLX
      Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?

      Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much […]

      Aug 21Yahoo FinanceAMLX

      This is the newest page. Registered accounts read further back.